CAPR (Capricor Therapeutics Inc.) Rasio Nilai Pasar marang Nilai Buku

Capricor Therapeutics (CAPR) is optimizing costs by outsourcing clinical testing and drug manufacturing to third-party contractors. Growing physician interest in Duchenne muscular dystrophy therapy provides significant growth potential. The business relies on a unique cell therapy system featuring the CAP-1002 platform, creating a closed-loop therapy cycle. The current metric stands at 1.42, and the market's valuation dynamics for the asset are illustrated in the chart below.

Patent-protected cell therapy developments and the success of Deramiocel trials create high added value for Capricor Therapeutics (CAPR). This indicator measures the market value premium over book capital, reflecting investor expectations for future earnings; therefore, a rising market-to-book ratio signals asset overvaluation and increased risks of a correction.